IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675 · see citing works

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · see citing works

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · see citing works

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works

BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

O’Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C. L., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,130 · see citing works

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Terpos, E., Kleber, M., Engelhardt, M. M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988 · see citing works

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744 · see citing works

Tutorial in biostatistics: the self‐controlled case series method

Whitaker, H. J., Paddy Farrington, C., Spiessens, B., & Musonda, P. (2006) · Statistics in Medicine · doi:10.1002/sim.2302 · Cited by 719 · see citing works

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664 · see citing works

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations

Girmenia, C., Cavo, M., Offidani, M., Scaglione, F., Corso, A., Raimondo, F. D., Musto, P., Petrucci, M. T., & Barosi, G. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.01.001 · Cited by 662 · see citing works

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 656 · see citing works

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., Hungria, V., Salwender, H. J., Suzuki, K., Kim, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30525-8 · Cited by 404 · see citing works

APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity

Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelley, M. J., Ramakrishnan, M., McCabe, S., Qiu, W., Kornuc, M., Xia, X.-Z., et al. (2000) · Nature Immunology · doi:10.1038/79802 · Cited by 362 · see citing works

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia

Barmettler, S., Ong, M., Farmer, J. R., Choi, H. K., & Walter, J. E. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4169 · Cited by 362 · see citing works

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Krönke, J., Facon, T., Salnikov, A. V., Lesley, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02657 · Cited by 304 · see citing works

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oekelen, O. V., Gleason, C., Agte, S., Srivastava, K., Beach, K. F., Aleman, A., Kappes, K., Banu, R., Bermúdez-González, M. C., Chernet, R. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.014 · Cited by 208 · see citing works

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

Lee, L. S. H., Bounds, D., Paterson, J. C., Herledan, G., Sully, K., Seestaller‐Wehr, L., Fieles, W. E., Tunstead, J. R., McCahon, L., Germaschewski, F., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14145 · Cited by 191 · see citing works

Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions

Anderson, D. R., Ali, K., Blanchette, V. S., Brouwers, M. C., Couban, S., Radmoor, P., Huebsch, L. B., Hume, H. A., McLeod, A. G., Meyer, R. M., et al. (2007) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2007.01.001 · Cited by 190 · see citing works

Monoclonal Gammopathy–Associated Peripheral Neuropathy: Diagnosis and Management

Chaudhry, H. M., Mauermann, M. L., & Rajkumar, S. V. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.003 · Cited by 152 · see citing works

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

D’Souza, A., Shah, N. D., Rodriguez, C., Voorhees, P. M., Weisel, K. C., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01504 · Cited by 134 · see citing works

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma

Wang, Y., Cao, J., Gu, W., Shi, M., Lan, J., Yan, Z., Jin, L., Xia, J., Ma, S., Liu, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01676 · Cited by 132 · see citing works

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy

Thiruvengadam, S. K., Sheng, Y., Huang, C.-Y., Bylsma, S., Lo, M., Kennedy, V., Natsuhara, K., Martin, T., Wolf, J., Shah, N., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2020004079 · Cited by 131 · see citing works

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

Aleman, A., Upadhyaya, B., Tuballes, K., Kappes, K., Gleason, C., Beach, K. F., Agte, S., Srivastava, K., Andre, D., Azad, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.015 · Cited by 73 · see citing works

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Wong, S. W. K., Bar, N., París, L., Hofmeister, C. C., Hansson, M., Santoro, A., Mateos, M., Rodríguez‐Otero, P., Lund, J., Encinas, C., et al. (2022) · Blood · doi:10.1182/blood-2022-159009 · Cited by 67 · see citing works

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Raje, N., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., et al. (2022) · Blood · doi:10.1182/blood-2022-166494 · Cited by 46 · see citing works

Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics

Lin, C., Shen, H., Zhou, S., Liu, M., Xu, A., Huang, S., Shen, C., & Zhou, F. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05412-w · Cited by 44 · see citing works

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients

Wu, X., Wang, L., Shen, L., He, L., & Tang, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01300-9 · Cited by 39 · see citing works

pneumonia in an infant with X-linked agammaglobulinemia

Alibrahim, A., Lepore, M. S., Lierl, M. B., Filipovich, A. H., & Assa’ad, A. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70363-x · Cited by 39 · see citing works

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Bumma, N., Richter, J. R., Brayer, J. B., Zonder, J. A., Dhodapkar, M. V., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., et al. (2022) · Blood · doi:10.1182/blood-2022-159969 · Cited by 38 · see citing works

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy

Terpos, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Briasoulis, Α., Gumeni, S., Malandrakis, P., Papanagnou, E., Migkou, M., Kanellias, N., Kastritis, E., et al. (2022) · Blood · doi:10.1182/blood.2021014989 · Cited by 37 · see citing works

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update

Romero, C., Díez, J.-M., & Gajardo, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00755-6 · Cited by 27 · see citing works

Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma

Lancman, G., Lozada, K. S., Athar, N., Jacobs, S. E., Doucette, J. T., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.026 · Cited by 22 · see citing works

Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response

Ramasamy, K., Sadler, R., Jeans, S., Weeden, P., Varghese, S., Turner, A., Larham, J., Gray, N., Carty, O., Barrett, J., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18066 · Cited by 22 · see citing works

Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia

Kanegane, H., Nakano, T., Shimono, Y., Zhao, M., & Miyawaki, T. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0322-5 · Cited by 21 · see citing works

X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii

Jongco, A. M., Gough, J. D., Sarnataro, K., Rosenthal, D. W., Moreau, J., Ponda, P., & Bonagura, V. R. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.10.008 · Cited by 16 · see citing works

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Lancman, G., Sastow, D. L., Aslanova, M., Moshier, E. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., et al. (2020) · Blood · doi:10.1182/blood-2020-140056 · Cited by 15 · see citing works

Neutralizing antibody responses against SARS‐CoV ‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination

Abdallah, A.-O. A., Mahmoudjafari, Z., Atieh, T., Ahmed, N., Cui, W., Shune, L. O., Mohan, M., McGuirk, J. P., Remker, C., Foss, M., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13826 · Cited by 11 · see citing works

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Lancman, G., Shyu, M., Metzger, M., Parsa, K., Cho, H. J., Parekh, S. S., Richter, J. R., Rodriguez, C., Rossi, A., Sanchez, L. J., et al. (2022) · Blood · doi:10.1182/blood-2022-163757 · Cited by 11 · see citing works

Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

van de Donk, N. W. C. J., Zweegman, S., Miguel, J. F. S., Dimopoulos, M. A., Cavo, M., Suzuki, K., Touzeau, C., Usmani, S. Z., Perrot, A., Pei, H., et al. (2020) · Blood · doi:10.1182/blood-2020-134923 · Cited by 9 · see citing works

X-linked Agammaglobulinemia Presenting with Multiviral Pneumonia

Arroyo, Y. M., Saindon, M., & Raina, J. S. (2020) · Cureus · doi:10.7759/cureus.7884 · Cited by 8 · see citing works

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study

Mikulski, D., Robak, P. J., Ryżewska, W., Stańczak, K., Kościelny, K., Góra‐Tybor, J., & Robak, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195908 · Cited by 6 · see citing works

Cytomegalovirus Pneumonia in a Patient with X-Linked Agammaglobulinemia: A Case Report

Wong, Y.-X., & Shyur, S. (2022) · Medicina · doi:10.3390/medicina58101457 · Cited by 2 · see citing works

Current understanding and management of CAR T cell-associated toxicities

Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 330 · see citing works

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Mohan, M., Monge, J., Shah, N. N., Luan, D., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01003-z · Cited by 106 · see citing works

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Frerichs, K. A., Verkleij, C. P. M., Mateos, M., Martin, T. G., Rodriguez, C., Nooka, A. K., Banerjee, A., Chastain, K. M., Perales‐Puchalt, A., Stephenson, T., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011658 · Cited by 105 · see citing works

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 94 · see citing works

Bispecific antibodies in the treatment of multiple myeloma

Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 94 · see citing works

Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review

Géraud, A., Hueso, T., Laparra, A., Bigé, N., Ouali, K., Cauquil, C. A., Stoclin, A., Danlos, F., Hollebecque, A., Ribrag, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114075 · Cited by 88 · see citing works

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 87 · see citing works

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

Jourdes, A., Cellerin, E., Touzeau, C., Harel, S., Denis, B., Escure, G., Faure, E., Jamard, S., Danion, F., Sonntag, C., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.02.023 · Cited by 77 · see citing works

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B. A., Nishimura, N., Farzana, T., Rueda, C., Chung, D. J., Landau, H. J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01043-5 · Cited by 53 · see citing works

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Sim, B. Z., Longhitano, A., Er, J., Harrison, S. J., Slavin, M. A., & Teh, B. W. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00808-8 · Cited by 50 · see citing works

Bispecific antibodies: unleashing a new era in oncology treatment

Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 50 · see citing works

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies

Bangolo, A., Amoozgar, B., Mansour, C., Zhang, L., Gill, S. K., Ip, A., & Cho, C. (2025) · Cancers · doi:10.3390/cancers17020282 · Cited by 47 · see citing works

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

Mohan, M., Szabó, A., Cheruvalath, H., Clennon, A., Bhatlapenumarthi, V., Patwari, A., Balev, M., Bhutani, D., Shrestha, A., Thanendrarajan, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01282-0 · Cited by 42 · see citing works

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Banerjee, R. K., Mohan, M., Rejeski, K., Puliafito, B. R., Cirstea, D. D., Kaur, G., Midha, S., McCaughan, G. J. B., Kumar, N. M., Mehra, N., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016490 · Cited by 40 · see citing works

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma

Firestone, R., Lesokhin, A. M., & Usmani, S. Z. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0176 · Cited by 33 · see citing works

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma

Stock, S., Bücklein, V., Blumenberg, V., Magno, G., Emhardt, A., Holzem, A. M. E., dos Santos, D. M. C., Schmidt, C., Grießhammer, S., Frölich, L., et al. (2025) · HemaSphere · doi:10.1002/hem3.70062 · Cited by 29 · see citing works

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma

Pan, D., & Richter, J. R. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00740-z · Cited by 27 · see citing works

Advances in the critical care management for patients with hematological malignancies

Azoulay, É., Zafrani, L., Nates, J. L., Maillard, A., Chean, D., Ferreyro, B. L., Nelson, J. E., Bauer, P. R., Puxty, K. A., Gutiérrez, C., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101306 · Cited by 25 · see citing works

IgG replacement in multiple myeloma

Wonnaparhown, A. M., Hilal, T., Squire, J. D., Freeman, C. M., & Fonseca, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01107-6 · Cited by 24 · see citing works

T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment

van de Donk, N. W. C. J., Rasche, L., Sidana, S., Zweegman, S., & Garfall, A. L. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0124 · Cited by 26 · see citing works

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

Razzo, B. M., Midha, S., Portuguese, A. J., Grajales-Cruz, A. F., Corraes, A. D. M. S., Costello, P., Liu, Y., Sperling, A. S., Nadeem, O., Dima, D., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0354 · Cited by 25 · see citing works

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

Rees, M., & Kumar, S. K. (2023) · Leukemia and Lymphoma · doi:10.1080/10428194.2023.2284088 · Cited by 19 · see citing works

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives

Waldschmidt, J. M., Rasche, L., Kortüm, K. M., & Einsele, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.11.012 · Cited by 21 · see citing works

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Tix, T., Alhomoud, M., Shouval, R., Iacoboni, G., Cliff, E. R. S., Hansen, D. K., Usmani, S. Z., Salles, G. A., Perales, M., dos Santos, D. M. C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.048 · Cited by 22 · see citing works

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

Bröckelmann, P. J., Cliff, E. R. S., Iacoboni, G., Simon, F., Horowitz, M. M., Keating, A., Mateos, M., Mohty, M., Sidana, S., Song, Y., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00051-1 · Cited by 20 · see citing works

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs

Jelinek, T., Žihala, D., Zabaleta, A., Kostopoulos, I. V., Souček, O., Venglár, O., Moreno, C., Fotiou, D., Radova, E., Tamariz‐Amador, L., et al. (2025) · Blood · doi:10.1182/blood.2025029572 · Cited by 20 · see citing works

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

Parrondo, R. D., Ailawadhi, S., & Cerchione, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394048 · Cited by 21 · see citing works

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review

Sassine, J., Siegrist, E. A., & Chemaly, R. F. (2025) · Viruses · doi:10.3390/v17010133 · Cited by 19 · see citing works

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma

Golmohammadi, M., Raza, S., Albayyadhi, M., Sholehrasa, H., Khouri, J., Williams, L., Hansen, D. K., Moradi, A., Xu, X., Albliwi, M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01334-5 · Cited by 18 · see citing works

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

Yee, A. J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01091-x · Cited by 17 · see citing works

Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies

Techaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., Thu, M. S., Hirankarn, N., & Pitakkitnukun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06524-6 · Cited by 14 · see citing works

Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient

Arvanitis, P., Farmakiotis, D., & Pelcovits, A. (2024) · Current Oncology · doi:10.3390/curroncol31050202 · Cited by 13 · see citing works

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Shrivastava, T., van Rhee, F., & Hadidi, S. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s370880 · Cited by 13 · see citing works

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1

Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Song, J., Uhlar, C., Chastain, K. M., et al. (2024) · Cancer · doi:10.1002/cncr.35665 · Cited by 12 · see citing works

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma

Dima, D., Banerjee, R., & Hansen, D. K. (2025) · Hematology · doi:10.1182/hematology.2025000721 · Cited by 11 · see citing works

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

Mo, C. C., Richardson, E., Calabretta, E., Corrado, F., Kocoglu, M. H., Baron, R. M., Connors, J. M., Iacobelli, M., Wei, L. J., Rapoport, A. P., et al. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101218 · Cited by 10 · see citing works

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Morè, S., Corvatta, L., Manieri, V. M., Morsia, E., & Offidani, M. (2024) · Cancers · doi:10.3390/cancers16122263 · Cited by 9 · see citing works

Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma

O’Donnell, E., Gift, T., Yousif, Z. K., Khandelwal, N., Desai, R., Huynh, L. Y., Clear, L., Pinaire, M., Ye, M., Banatwala, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015477 · Cited by 9 · see citing works

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis

Štork, M., Radocha, J., Mihályová, J., Špıčka, I., Pika, T., Jungová, A., Boichuk, I., Mensikova, K., Štraub, J., Sedlák, F., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06529-1 · Cited by 9 · see citing works

Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab

Smits, F., Groen, K., Korst, C. L. B. M., Frerichs, K. A., Kuipers, I., Kruyswijk, S., de Ruijter, M. E. M., Nasserinejad, K., Zweegman, S., & van de Donk, N. W. C. J. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01451-9 · Cited by 9 · see citing works

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach

Kannan, A., Jeffrey, K., Misbah, S., & Ramasamy, K. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101287 · Cited by 9 · see citing works

Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians

Lupia, T., Cani, L., Bringhen, S., Rosa, F. G. D., Bruno, B., Mikulska, M., Corcione, S., & Mina, R. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.002 · Cited by 8 · see citing works

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis

Li, W., Zhao, D., Yu, J., Dong, W., Wang, Z., & Yan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565407 · Cited by 8 · see citing works

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis

Hoffmann, M., Jeker, B., Huynh‐Do, U., Banz, Y., Godau, J., Weber, E., Bacher, U., & Pabst, T. (2025) · Hematological Oncology · doi:10.1002/hon.70120 · Cited by 8 · see citing works

Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies

Zhou, X., Waldschmidt, J. M., & Einsele, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101342 · Cited by 8 · see citing works

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS

Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17091514 · Cited by 7 · see citing works

Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies

Piron, B., Rodrigo, L., Tessoulin, B., Gastinne, T., Dubruille, V., Letailleur, V., Antier, C., Lok, A., Leroy, E., Moreau, P., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.024 · Cited by 7 · see citing works

Infections after bispecific antibodies in B-cell lymphomas

Kim, D. H., Lee, N., Koh, Y., Jo, H. J., Kang, C. K., Choe, P. G., Park, W. B., Lee, C. M., Byun, J. M., & Kim, N. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017366 · Cited by 7 · see citing works

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

Portuguese, A. J., Davis, J. A., Raza, S., Puglianini, O. A. C., Freeman, C., Alsina, M., Wright, C., Blue, B. J., Baz, R. C., Shain, K. H., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01477-z · Cited by 7 · see citing works

The impact of institutional measures on optimal use of intravenous immunoglobulin

Champagne, J., Desîlets, A., Roy, G., Landon‐Cardinal, O., Chapdelaine, H., Matte, G., Bouchard, C., Rioux‐Massé, B., & Lemay, A. (2024) · Transfusion · doi:10.1111/trf.18031 · Cited by 7 · see citing works

Are we there yet? CAR ‐T therapy in multiple myeloma

Mirvis, E., & Benjamin, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19896 · Cited by 7 · see citing works

Supportive care in myeloma—when treating the clone alone is not enough

Zweegman, S., & van de Donk, N. W. C. J. (2024) · Hematology · doi:10.1182/hematology.2024000579 · Cited by 7 · see citing works

Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study

Derman, B. A., Roach, M., Lin, D., Wu, B., Murphy, R., Kim, N., Doyle, M., Prood, N., Fowler, J., Marshall, A., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2352856 · Cited by 6 · see citing works

Mechanistic Insights and Advances of Bispecific T Cell Engaging Antibodies Therapy in Multiple Myeloma

Tang, T. F., Cheong, C. S., Looi, C. Y., Wong, W. F., & Gan, G. G. (2025) · Medicina · doi:10.3390/medicina61122113 · Cited by 6 · see citing works

Defining infection risk of bispecific antibodies for myeloma

Hammond, S. P. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013813 · Cited by 5 · see citing works

Understanding Infection Risk with Anti-BCMA Bispecific Antibodies

Garfall, A. L., & Stadtmauer, E. A. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0157 · Cited by 5 · see citing works

The Real World Impact of Immunoglobulin Replacement Therapy on Severe Bacterial Infection for Patients With Hypogammaglobulinemia Secondary to Hematologic Malignancies: A Japanese Claims Database Study

Mihara, K., Kawase, T., Miyama, T., Iwasaki, K., Shoji, A., & Matsumaru, M. (2025) · eJHaem · doi:10.1002/jha2.70091 · Cited by 4 · see citing works

A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma

Nishimura, N., Nakashima, H., Yoshikuni, K., Numata, A., & Ogawa, R. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00506-6 · Cited by 4 · see citing works

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies

Paulsen, J. S., & Slørdahl, T. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722579 · Cited by 4 · see citing works

Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?

Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4 · see citing works

Towards personalized and rational use of immunoglobulins amid expanding indications and shortages

Goubran, H. A., Ragab, G., Seghatchian, J., & Burnouf, T. P. R. (2024) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2024.103987 · Cited by 4 · see citing works

Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management

Saltarella, I., Altamura, C., Solimando, A. G., D’Amore, S., Ria, R., Vacca, A., Desaphy, J., & Frassanito, M. A. (2024) · Cancers · doi:10.3390/cancers16183190 · Cited by 4 · see citing works

Treatment of elderly and frail myeloma patients

Shih, S. C.-M., Visram, A., & Mian, H. S. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4 · see citing works

Practical insights into bispecific antibody therapy in multiple myeloma

Kawasaki, Y., Winger, S., Esteghamat, N., Rosenberg, A. S., & Beechinor, R. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2445145 · Cited by 4 · see citing works

Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions

Wonnaparhown, A. M., Hilal, T., Chong, A. C., & Fonseca, R. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101316 · Cited by 4 · see citing works

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy

Davis, J. A., McGann, M., Marini, J., & Hashmi, H. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344650 · Cited by 4 · see citing works

Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention

Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 5 · see citing works

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Talarico, M., Barbato, S., Maisnar, V., Delimpasi, S., Puppi, M., Rizzello, I., Pantani, L., Tacchetti, P., Martello, M., Vigliotta, I., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06326-3 · Cited by 4 · see citing works

Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies – A review

Dye, B., Gromer, D. J., Bibi, M., Siegrist, E. A., & Sassine, J. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.007 · Cited by 3 · see citing works

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Chakraborty, R., Bhutani, D., & Lentzsch, S. (2025) · Hematology · doi:10.1182/hematology.2025000760 · Cited by 3 · see citing works

Reshaping multiple myeloma treatment: recent breakthroughs

Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 3 · see citing works

Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit

Rodriguez, C., Touzeau, C., Crusoé, E. D. Q., Pericole, F. V., & Hungria, V. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.015 · Cited by 3 · see citing works

Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience

Marneni, N., Lessans, S., Dholaria, B., Sengsayadeth, S. M., Biltibo, E. A., Patel, V. G., Bhaskar, S., Jayani, R., Mohan, S. R., Kishtagari, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721820 · Cited by 3 · see citing works

Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives

Larue, M., Bitoun, S., Zuber, J., Michel, M., & Talbot, A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104060 · Cited by 3 · see citing works

How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies

Rejeski, K., Banerjee, R. K., & Hill, J. A. (2026) · Blood · doi:10.1182/blood.2025032298 · Cited by 3 · see citing works

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Howard, A. J., Concepcion, I., Wang, A. X., Hamadeh, I. S., Hultcrantz, M. L., Mailankody, S., Tan, C. R. C., Korde, N., Lesokhin, A. M., Hassoun, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012871 · Cited by 3 · see citing works

Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group

Moore, S. E., Miller, H., Parrish, C., Seymour, F., Miller, L. J., Chandler, T., Land, J., Karpha, I., Brearton, G., Thompson, S., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70041 · Cited by 4 · see citing works

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement

Lancman, G., Song, K., White, D. J., Crosbie, T., Sharif, I., Emond, M., Raza, M. S., Elias, M., Kaedbey, R., & Chu, M. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446995 · Cited by 3 · see citing works

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

Guo, Z. K., Zhu, J., Wang, J., Wang, L., Tang, F., Huang, H., Xia, Z., Liu, L., Wang, D., Zhong, N., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1544025 · Cited by 2 · see citing works

CAR-T for multiple myeloma: practice pearls

O'Leary, D., & Bachanová, V. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02582-6 · Cited by 2 · see citing works

Bispecific T-cell engager therapy for multiple myeloma

Cirstea, D. D., Puliafito, B. R., Kim, B. E., Lei, M., & Raje, N. S. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101649 · Cited by 2 · see citing works

The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma

Zhou, X., Luo, E., Chen, W., Deng, Y., Wu, B., Jiang, X., Zhang, K., & Lai, F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1593405 · Cited by 2 · see citing works

Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

Bilbao, I., Ansón, M., Villar, S., Pineda, I., Gárriz, L., Pina‐Sánchez, M., Tamariz‐Amador, L., Rodríguez‐Otero, P., Yuste, J. R., & del Pozo, J. L. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf672 · Cited by 2 · see citing works

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis

Tan, C. R., Usmani, S. Z., Derkach, A., Corraes, A. D. M. S., Parrondo, R. D., Ailawadhi, S., Asoori, S., Dave, M., Popat, R., Morjaria, O., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019231 · Cited by 2 · see citing works

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K. C., Straßl, I., Krauth, M. T., Knop, S., Winder, T., & Steiner, N. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07140-8 · Cited by 2 · see citing works

T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement

van Voss, M. R. H., Molenaar, R. J., Korst, C. L. B. M., Bartelink, I. H., Baglio, S. R., Kruyswijk, S., de Ruijter, M. E. M., Zweegman, S., Kuipers, M. T., & van de Donk, N. W. C. J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2397436 · Cited by 2 · see citing works

Infections during novel myeloma therapies

Liu, A. J., Slavin, M. A., Harrison, S. J., & Teh, B. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2428819 · Cited by 2 · see citing works

Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study

Ghia, D., Thota, P., Ritchie, T., Rana, H., Minhas, R., Moolji, J., Ritchie, B. C., & Adatia, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316797 · Cited by 2 · see citing works

Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma

Giles, H. V., & Kishore, B. (2026) · Antibodies · doi:10.3390/antib15010005 · Cited by 2 · see citing works

Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies

Goede, J. S., Baumann, C. K., Cathomas, R. L., Khanna, N., Lambert, J., Lehmann, T., Mey, U., Seebach, J. D., Steiner, U. C., Tschan‐Plessl, A., et al. (2024) · Swiss Medical Weekly · doi:10.57187/s.3559 · Cited by 1 · see citing works

An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma

Bayly-McCredie, E., Prince, H. M., Yannakou, C. K., & Fiorenza, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2479631 · Cited by 1 · see citing works

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Pelland, A.-A., Dumas, M., Lemieux‐Blanchard, É., LeBlanc, R., Côté, J. A., Boudreault, J., Duquette, D., Kaedbey, R., Lalancette, M., Larose, F., et al. (2025) · Current Oncology · doi:10.3390/curroncol32040238 · Cited by 1 · see citing works

Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma–Experience from Asian Countries

Soekojo, C. Y., Chung, S. J., Tsai, M.-T., Chen, W.-M., Huang, J., Kim, J. S., Lee, D., Min, C., Suzuki, K., Swaminathan, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.005 · Cited by 1 · see citing works

Reversing the sequence: Efficacy of BCMA‐directed therapy following progression on GPRC5D ‐directed therapies in relapsed multiple myeloma

Joiner, L., Giri, S., Ravi, G., Godby, K. N., Hagedorn, C., Costa, L. J., & Bal, S. (2025) · British Journal of Haematology · doi:10.1111/bjh.70176 · Cited by 1 · see citing works

Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma

Kitamura, A., Fujita, S., Isono, Y., Nakano, T., Morino, T., Tozuka, K., Kudo, H., Abe, R., Kohashi, S., & Toyama, T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102851 · Cited by 1 · see citing works

Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma

Suzuki, T., & Iida, S. (2025) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.25038 · Cited by 1 · see citing works

Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions

Piron, B., Moreau, P., & Touzeau, C. (2026) · Biologics · doi:10.2147/btt.s539066 · Cited by 1 · see citing works

Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies

Cao, W., meng, F., Feng, S., Zhao, M., Song, J., Sun, Y., Cao, W., Tian, W., Hu, Y., Fan, F., et al. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70107 · Cited by 1 · see citing works

Significant burden of low-grade infections in patients treated with T-cell−engaging therapies for multiple myeloma

Mersi, J., Burow, L., Zhou, X., Eisele, F., Fante, M. A., Riedhammer, C., Stich, A., Isberner, N., Afrin, N., Duell, J., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017889 · Cited by 1 · see citing works

Infektionen unter Therapie mit bispezifischen Antikörpern bei malignen Lymphomen, dem multiplen Myelom und der akuten lymphatischen Leukämie

Ruckdeschel, A. M., von Herder, J., Giesen, N., Sandherr, M., Rieger, C., & Teschner, D. (2026) · best practice onkologie · doi:10.1007/s11654-026-00714-y · Cited by 1 · see citing works

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Lancman, G., Parsa, K., Rodriguez, C., Richter, J. R., Cho, H. J., Parekh, S. S., Richard, S., Rossi, A., Sanchez, L. J., Thibaud, S., et al. (2022) · Blood · doi:10.1182/blood-2022-163733 · Cited by 48 · see citing works

Immunoglobulin May Prevent Infections in Patients With Multiple Myeloma

(2023) · Oncology Times · doi:10.1097/01.cot.0000996488.11406.21

Prophylactic intravenous immunoglobulin in patients receiving BCMA-targeted bispecific antibody therapy for multiple myeloma: A systematic review and meta-analysis

Bezerra, G. N., Passos, P. R. C., Noronha, M. M., Luciano, P. H. C., Filho, V. O. C., Ferri, G. M., & Filho, C. M. D. O. (2025) · Blood · doi:10.1182/blood-2025-5754 · Cited by 2 · see citing works

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

Cani, L., Scott, S. A., Roberts, D., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Lonial, S., Nooka, A. K., & Kaufman, J. L. (2025) · Haematologica · doi:10.3324/haematol.2025.288187 · Cited by 8 · see citing works

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis

Mazahreh, F., Mazahreh, L., Schinke, C., Thanendrarajan, S., Zangari, M., Shaughnessy, J. D., Zhan, F., van Rhee, F., & Al Hadidi, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009435 · Cited by 142 · see citing works